Development of PEA3 as a Potential Gene Therapy Agent for Breast Cancer
Abstract
13. ABSTRACT (Maximum 200 The HER-2/neu gene is frequently amplified and /or its protein product, p185, is frequently overexpressed in a number of human cancers. Overexpression of p185 correlates with poor prognosis and low survival rates in breast and ovarian cancer patients. Downregulation of HER-2/neu gene is a way to reverse the transformation phenotype induced by HER-2/neu. In this project, the effects of PEA3, a member of ets oncogene family of transcriptional regulatory factors, on HER-2/neu expression were investigated to learn whether PEA3 plays a role in HER-2/neu induced transformation and could be developed to a gene therapeutic agent. This progress report includes our recent data which demonstrating that, PEA3 is indeed a trans-repressor of HER-2/neu promoter in HER-2/neu overexpressing human cancer cells.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 1997
- Accession Number
- ADA334912
Entities
People
- Xing Xiangming
Organizations
- The University of Texas MD Anderson Cancer Center